Page 2 - புத்திசாலி வளர்ச்சி செயல்பாட்டு ப்ரோக்ர்யாம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

86 million pln to 33 Accelerators for Poland Prize

86 million pln to 33 Accelerators for Poland Prize. PARP (the Polish Agency for Enterprise Development) has announceed the results of the “Accelerative Programs – Poland Prize” competition. 33 accelerators took part in the competition, presenting their original concepts of searching for and bringing foreign teams to Poland ready to implement innovative solutions in our country. The value of submitted applications exceeded PLN 326 million, compared to PLN 60 million initially available in the competition. The high level of projects resulted in the selection of as many as 9 operators and the competition budget was increased to over PLN 86.2 million. The competition is financed by the European funds of the Intelligent Development Operational Program.

Intelligent development operational programAgency for enterprise developmentPolish agencyEnterprise developmentIntelligent development operationalபுத்திசாலி வளர்ச்சி செயல்பாட்டு ப்ரோக்ர்யாம்நிறுவன வளர்ச்சிபுத்திசாலி வளர்ச்சி செயல்பாட்டு

WPD Pharmaceuticals to Attend the 10th Congress of the Polish Society of Pediatric Oncology and Hematology and Present Assumption of the Phase 1 Study with Berubicin in Pediatric Malignant Gliomas

Share: WPD Pharmaceuticals Inc. (CSE:WBIO)(FSE: 8SV1) (the Company or WPD ) a clinical-stage pharmaceutical company, is pleased to announce that it will attend the 10 th Annual Congress of the Polish Society of Pediatric Oncology and Hematology to be held on May 6-8, 2021. During the Congress, WPD will present the key assumptions of the WPD-201P Clinical Trial Protocol, which is planned to start in Q2 2021, as a part of the research project: New approach to glioblastoma treatment addressing the critical unmet medical need , granted by National Research and Development Center ( NRDC ) and co-financed by the European Union, under the Smart Growth Operational Program 2014-2020.

United statesNew yorkUnited kingdomBritish columbiaMariusz olejniczakThomas renaudMoleculin biotech incSociety of pediatric oncologyNational researchSmart growth operational programNeither the canadian securities exchangeEuropean unionPharmaceuticals incWake forest universityInvestment decisionsUniversity of texas md anderson cancer center

Even 280 thousand PLN subsidies for entrepreneurs The call for applications has started

Even 280 thousand PLN subsidies for entrepreneurs The call for applications has started
biznespolska.pl - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biznespolska.pl Daily Mail and Mail on Sunday newspapers.

Intelligent development operational programEuropean commissionIntelligent development operationalபுத்திசாலி வளர்ச்சி செயல்பாட்டு ப்ரோக்ர்யாம்ஐரோப்பிய தரகுபுத்திசாலி வளர்ச்சி செயல்பாட்டு

WPD and CNS Pharmaceuticals Announce Positive Opinion of the Polish Central Ethics Committee for the WPD-201 Study and Central IRB Study Level Approval for the CNS-201 Study

Share this article HOUSTON, Feb. 18, 2021 /PRNewswire/ WPD Pharmaceuticals (CSE:WBIO) (8SV1.F) ( WPD ) and CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ( CNS or the Company ), biopharmaceutical companies specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that WPD Pharmaceuticals received a positive opinion of the Lower Silesian Medical Chamber Ethics Committee in Wrocław, Poland for its planned upcoming Berubicin clinical trial in adults with Glioblastoma Muliforme (GBM) under the WPD-201 Clinical Trial Protocol. CNS Pharmaceuticals has received study level Central IRB Approval from the Central IRB for the CNS-201 Clinical Trial Protocol.

United statesMariusz olejniczakJohn climacoMoleculin biotech incMd anderson cancer centerSmart growth operational programEuropean unionEthics committeePharmaceuticals incWake forest universityOffice for registration of medicinal productsCentral ethics committeeNational centerCompetent authorityDrug administrationWake forest university health sciences